New lung cancer drug trial begins

29 March 2011

Trials for a new lung cancer treatment have begun in Oxford.
The experimental treatment is aimed at patients who have failed to respond to traditional chemotherapy medication.

Dr Denis Talbot, trial chief investigator at the new Oxford Cancer Research Centre, said: "We hope that it may increase rates of survival for lung cancer patients."

He claimed that preliminary results were encouraging and that if the benefits were borne out in this more substantial trial then the drug could be developed into a clinical treatment.

Dr Talbot said that late diagnosis was one of the issues of lung cancer treatment.

"The majority, 65-75 per cent, of lung cancer patients are diagnosed when the cancer has already become aggressive, which makes it more difficult to treat successfully," he said.

"There's an urgent need to develop new medicines which may provide additional options for these patients," he concluded.

Posted by Philip Briggs

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)